18F-FDG PET/CT与解剖影像评估Erdheim-Chester病病变范围及临床试验资格的对比:注册研究50例结果
该注册研究纳入50例Erdheim-Chester病(ECD)患者,比较18F-FDG PET/CT与CT/MRI在评估病变范围和临床试验资格中的作用。在178个可测量病变中,仅mPERCIST可测量136个(76%),仅RECIST可测量2个(1%),两者均可测量40个(22%);患者层面仅mPERCIST可测量者30例(60%),仅RECIST可测量者0例(p<0.0001)。结论认为PET/CT补充了解剖影像对病变范围的评估,并提高符合正式疗效标准及临床试验资格的患者识别。
要点
- 18F-FDG PET/CT较CT/MRI多检出20%的病变部位,仅PET检出67个。
- 76%的可测量病变仅符合mPERCIST标准,仅1%仅符合RECIST标准。
- 60%患者仅mPERCIST可测量,无患者仅RECIST可测量(p<0.0001)。
核心结论
- 与解剖影像相比,18F-FDG PET/CT增强ECD病变范围评估并提高可测量病变及临床试验资格识别。
- 器官特异性解剖影像可补充提供更详细的解剖细节。
研究设计与样本
- 前瞻性注册研究,回顾分析入组ECD患者的18F-FDG PET/CT及对应CT或MRI。
- 共纳入50例患者,平均年龄51.5岁(范围18-70岁)。
- 病变按检测方式(仅PET、仅CT/MRI、两者)及可测量标准(仅mPERCIST、仅RECIST、两者)分类。
- 采用描述性分析及配对t检验进行组间比较。
主要发现
- 178个可测量病变中,仅mPERCIST可测量136个(76%),仅RECIST可测量2个(1%),两者均可测量40个(22%)。
- 患者层面,17例(34%)同时有mPERCIST和RECIST可测量病变,30例(60%)仅有mPERCIST可测量病变,0例仅有RECIST可测量病变(p<0.0001)。
关键数值与推荐
- 病变可测量性分别采用modified PERCIST(mPERCIST)和RECIST标准评估。
- 患者层面mPERCIST与RECIST可测量病变分布差异有统计学意义(p<0.0001)。
临床怎么用
- 在ECD患者临床试验筛选中,18F-FDG PET/CT应作为评估病变范围和可测量性的重要手段。
- mPERCIST标准较RECIST识别更多可测量病变和合格患者,建议优先采用代谢标准评估。
- 器官特异性解剖影像(如脑MRI)应与PET/CT互补使用以详细刻画病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aim of this study was to [1] characterize distribution of Erdheim-Chester Disease (ECD) by 18F-FDG PET/CT and [2] determine the utility of metabolic (18F-FDG PET/CT) imaging versus anatomic imaging (CT or MRI) in evaluating ECD patients for clinical trial eligibility. METHODS: 18F-FDG PET/CT and corresponding CT or MRI studies for ECD patients enrolled in a prospective registry study were reviewed. Sites of disease were classified as [1] detectable by 18F-FDG PET only, CT/MRI only, or both and as [2] measurable by modified PERCIST (mPERCIST) only, RECIST only, or both. Descriptive analysis was performed and paired t test for between-group comparisons. RESULTS: Fifty patients were included (mean age 51.5 years; range 18-70 years). Three hundred thirty-three disease sites were detected among all imaging modalities, 188 (56%) by both 18F-FDG PET and CT/MRI, 67 (20%) by 18F-FDG PET only, 75 (23%) by MRI brain only, and 3 (1%) by CT only. Of 178 disease sites measurable by mPERCIST or RECIST, 40 (22%) were measurable by both criteria, 136 (76%) by mPERCIST only, and 2 (1%) by RECIST only. On the patient level, 17 (34%) had mPERCIST and RECIST measurable disease, 30 (60%) had mPERCIST measurable disease only, and 0 had RECIST measurable disease only (p < 0.0001). CONCLUSION: Compared with anatomic imaging, 18F-FDG PET/CT augments evaluation of disease extent in ECD and increases identification of disease sites measurable by formal response criteria and therefore eligibility for clinical trials. Complementary organ-specific anatomic imaging offers the capacity to characterize sites of disease in greater anatomic detail. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03329274.
引用
- Kirchner J, Hatzoglou V, Buthorn JB, et al. 18F-FDG PET/CT versus anatomic imaging for evaluating disease extent and clinical trial eligibility in Erdheim-Chester disease: results from 50 patients in a registry study. Eur J Nucl Med Mol Imaging. 2020. PMID: 33057928. doi:10.1007/s00259-020-05047-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。